Role of DCLK1 in oncogenic signaling (Review)
- PMID: 36148883
- DOI: 10.3892/ijo.2022.5427
Role of DCLK1 in oncogenic signaling (Review)
Abstract
Doublecortin‑like kinase 1 (DCLK1) has been identified as a novel biomarker of cancer stem cells among several different cancer types, including colon, breast, pancreas, kidney, liver, stomach and esophageal cancers. Studies have demonstrated that DCLK1 regulates tumorigenesis and epithelial‑mesenchymal transformation via several important pathways, such as Notch, Wnt/β‑catenin, RAS and multiple microRNAs. The function and biological mechanisms, including their association with the molecular structure and isoforms of DCLK1, are gradually being elucidated. However, the currently available knowledge regarding DCLK1 in terms of developing effective anti‑cancer drugs remains incomplete. In the present review, the molecular characteristics, biomarker function and biological mechanisms of DCLK1 are summarized and DCLK1 is proposed as a potential anti‑tumor target via the glucose metabolism pathway.
Keywords: cancer stem cells; doublecortin‑like kinase 1; metabolism; molecular structure and function; signaling pathway.
Similar articles
-
DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.Pflugers Arch. 2020 Aug;472(8):1041-1049. doi: 10.1007/s00424-020-02415-z. Epub 2020 Jun 12. Pflugers Arch. 2020. PMID: 32533239
-
Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism.Sci Rep. 2020 Jun 29;10(1):10578. doi: 10.1038/s41598-020-67401-y. Sci Rep. 2020. PMID: 32601309 Free PMC article.
-
Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.Clin Transl Med. 2022 May;12(5):e743. doi: 10.1002/ctm2.743. Clin Transl Med. 2022. PMID: 35522902 Free PMC article.
-
DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target.Int J Cancer. 2025 Jun 1;156(11):2068-2086. doi: 10.1002/ijc.35365. Epub 2025 Mar 8. Int J Cancer. 2025. PMID: 40056091 Review.
-
Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.Int J Mol Sci. 2023 Nov 16;24(22):16407. doi: 10.3390/ijms242216407. Int J Mol Sci. 2023. PMID: 38003596 Free PMC article. Review.
Cited by
-
Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients.Breast Cancer (Dove Med Press). 2024 Sep 18;16:631-643. doi: 10.2147/BCTT.S478328. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39310782 Free PMC article.
-
Doublecortin-like kinase 1 activates NF-κB to induce inflammatory responses by binding directly to IKKβ.Cell Death Differ. 2023 May;30(5):1184-1197. doi: 10.1038/s41418-023-01147-8. Epub 2023 Mar 13. Cell Death Differ. 2023. PMID: 36914767 Free PMC article.
-
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.Front Oncol. 2023 Nov 9;13:1244781. doi: 10.3389/fonc.2023.1244781. eCollection 2023. Front Oncol. 2023. PMID: 38023167 Free PMC article. Review.
-
Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway.Cell Death Dis. 2023 Jul 13;14(7):419. doi: 10.1038/s41419-023-05960-4. Cell Death Dis. 2023. PMID: 37443105 Free PMC article.
-
A Novel D-peptide modulates DCLK1 Gelsolin interactions, reducing PDAC tumor growth.Res Sq [Preprint]. 2025 Mar 11:rs.3.rs-6099914. doi: 10.21203/rs.3.rs-6099914/v1. Res Sq. 2025. PMID: 40162222 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources